HF Advisory Group LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,484 shares of the company’s stock, valued at approximately $1,852,000. Johnson & Johnson makes up approximately 1.9% of HF Advisory Group LLC’s investment portfolio, making the stock its 10th largest holding.
Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Lincoln Capital Corp raised its stake in Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares during the period. Ieq Capital LLC raised its stake in shares of Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares during the last quarter. RFG Advisory LLC raised its stake in shares of Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after purchasing an additional 594 shares during the last quarter. Willis Investment Counsel raised its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after purchasing an additional 1,358 shares during the last quarter. Finally, Wambolt & Associates LLC raised its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after purchasing an additional 355 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $162.68 on Monday. The stock has a fifty day simple moving average of $158.33 and a two-hundred day simple moving average of $166.98. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35. The firm has a market cap of $422.76 billion, a price-to-earnings ratio of 34.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.77 and a debt-to-equity ratio of 0.49.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on JNJ shares. Raymond James lowered their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Morgan Stanley increased their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Piper Sandler decreased their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $173.00.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 5/1 – 5/5
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
